Roth MKM Sticks to Its Buy Rating for Stereotaxis (STXS)
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Wittes covers the Healthcare sector, focusing on stocks such as Globus Medical, Allurion Technologies, and Monogram Orthopaedics Inc. According to TipRanks, Wittes has an average return of 2.7% and a 48.06% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.67 average price target, which is a 125.60% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.
STXS market cap is currently $183.1M and has a P/E ratio of -7.17.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STXS in relation to earlier this year. Most recently, in March 2025, Isaac Paul J , a Director at STXS bought 38,000.00 shares for a total of $68,780.00.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 days ago
- Business Insider
3 'Strong Buy' Value Stocks to Buy Now, 8/13/2025, According to Analysts
Value stocks offer stability for investors by focusing on companies that seem underpriced compared to their actual worth. This approach involves looking for stocks with strong fundamentals and growth potential. By investing in these stocks, investors can achieve significant returns once the market recognizes their true value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One way to identify value stocks is by comparing a company's price-to-earnings (P/E) ratio with industry averages or its historical P/E ratios. This ratio compares a company's stock price to its earnings per share. It must be noted that a lower P/E ratio may indicate that the stock is undervalued. Along with this, we have zeroed in on stocks that have received 'Strong Buy' ratings from Wall Street analysts. Here Are This Week's Stocks NICE Ltd. (NICE) – This software company provides cloud and on-premises solutions for customer experience, compliance, and financial crime prevention. It has a Strong Buy analyst consensus rating and an average price target of $206.14, implying a 39.05% upside potential from the current levels. The company's P/E of 19.82x reflects a 29.5% discount to the Technology sector's median of 28.10. Delta Air Lines (DAL) – This major American airline provides domestic and international passenger and cargo services. Its average price target of $67.50 implies a 14.93% upside potential from the current levels. DAL stock has a Strong Buy consensus rating. Trading at a P/E of 8.48x, the company is valued 66.1% below the Industrial sector's median multiple of 25.00. Post Holdings (POST) – This consumer packaged goods company is known for its branded and private-label foods. It has a Strong Buy analyst consensus rating and an average price target of $127.70, implying a 17.73% upside potential from the current levels. With a P/E ratio of 18.33x, the stock is priced at an 18.1% discount to the Consumer Defensive sector's median of 22.38. What Is TipRanks' Smart Value Newsletter? TipRanks' Smart Value Newsletter helps investors identify high-potential value stocks with strong fundamentals and long-term growth potential, based on TipRanks' data and analysis. The newsletter, published weekly, includes macroeconomic, market-wide, and company-specific analysis to help investors understand the trends that affect value investing.
Business Insider
09-08-2025
- Business Insider
Analysts' Top Healthcare Picks: Stereotaxis (STXS), Tectonic Therapeutic (TECX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stereotaxis (STXS – Research Report) and Tectonic Therapeutic (TECX – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Stereotaxis (STXS) Roth MKM analyst Jason Wittes reiterated a Buy rating on Stereotaxis today and set a price target of $5.00. The company's shares closed last Friday at $2.51. According to Wittes is a 4-star analyst with an average return of 4.3% and a 49.1% success rate. Wittes covers the Healthcare sector, focusing on stocks such as TriSalus Life Sciences, Zimmer Biomet Holdings, and Allurion Technologies. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.50 average price target, which is a 95.7% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. Tectonic Therapeutic (TECX) In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Tectonic Therapeutic, with a price target of $85.00. The company's shares closed last Friday at $22.00. According to Ear has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.0% and a 34.1% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Cartesian Therapeutics, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tectonic Therapeutic with a $81.50 average price target, which is a 288.1% upside from current levels. In a report issued on August 6, Leerink Partners also maintained a Buy rating on the stock.
Yahoo
23-07-2025
- Yahoo
Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What: Stereotaxis second quarter 2025 financial results conference call When: Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (International) and give the participant pass code 1064613. Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis' website at Call Replay: A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit Investor Contacts:David L. FischelChairman and Chief Executive Officer Kimberly PeeryChief Financial Officer 314-678-6100Investors@
